Amgen Inc. said the U.S. FDA granted priority review to the company’s request to add important heart safety data to the label of its expensive injectable cholesterol drug Repatha.

Novo Nordisk is considering options ahead of key heart safety data for its diabetes drug Victoza and could run a further clinical study if necessary, the Danish company’s research head said on Wednesday. The outcome of Novo’s current cardiovascular trial, known as LEADER, has become critical following the unprecedented success of Eli Lilly and Boehringer Ingelheim’s […]